Nipah virus (NiV): a ‘new’ addition to the ever changing landscape of infections. by James, S. et al.
725 
 
Nepal Journal of Epidemiology 
 
 
 
Nipah virus (NiV): a ‘new’ addition to the ever changing landscape of infections  
Sruthi James1, Indrajit Banerjee2, Brijesh Sathian3, Edwin van Teijlingen4 
 
 
 
 
 
 
 
 
 
 
Copyright © 2018 CEA& INEA. Published online by NepJOL-INASP. 
 www.nepjol.info/index.php/NJE  
 
Public Health professionals and researchers always need to be 
on their toes as the pool of viruses is forever changing.  One 
recent example of this change is the Nipah virus (NiV).  This 
infection is a type of zoonosis, emerging from the family of 
Paramyxoviridae, genus Henipavirus (RNA virus) and the 
natural host is Pteropus fruit bat [1-3]. It is transmitted from 
infected animals to humans through direct contact and 
contaminated food like date palm sap. The patients are often 
asymptomatic and few suffers from acute respiratory 
infections and fatal encephalitis with a case fatality rate of 45- 
75% [3].  
NiV was identified initially in Malaysia in early 1999 among 
farmers and people who has close contact with pigs during an 
outbreak of Encephalitis and respiratory illness. Its name 
originated from the Malaysian village Sungai Nipah, [1, 2]. 
During this outbreak, nearly 300 people were believed to be 
infected with 105 casualties and more than a million pigs were 
slaughtered to prevent the outbreak from spreading. Although 
no more cases have been reported in Malaysia [1, 2], it moved 
to the neighbouring State of Singapore in 1999. 
Since its first attacks in Malaysia and Singapore, the NiV has 
appeared in Siliguri, West Bengal (India) in 2001 with 
evidence of person-to-person transmission in hospital settings 
(nosocomial infection) [4].  Sixty six cases with 45 deaths 
(68% of the cases) were reported in two outbreaks [5]. A 
further small outbreak of five people occurred in Nadia on 
2007 with a 100% fatality rate of five people. 
In Bangladesh, several outbreaks of Nipah encephalitis have 
been reported. A total of 209 cases in 20 districts of whom 161 
(77%) died. The first outbreak was in Meherpur (2001) with 
death rate of nine out of 13 cases. Since then a series of 
concurrent epidemics occurred untill 2012. In January 2003, 
eight deaths (n=12) were reported in Naagaon. Two outbreaks 
in 2004 reported a death rate of 23 (n=31) in Rajbari and 27 
(n=36) in Faridpur and 11 out of 12 people lost their lives in 
the Tangail epidemic of early 2005. From January to April 
2007, nine people died three (n=7) from Thakuragaon, five 
(n=8) from Kushtia, Pabnaand Natore and one (n=3) from 
Naogaon. Manikgonj sawa 100% (n=5) fatality rate in Feb 
2008. In April 2008, Rajbari and Faridpur again suffered from 
NiV with a mortality rate of five out of seven cases, but in 
Gaibandha, Rangpur and Nilphamari, no deaths (0%) were 
reported among three cases.  [1, 2].  
Without any reduction in the series of epidemic, surprisingly 
the virus moved to other new places in Bangladesh such as 
Gopalganj, Madaripur along with Faridpur and Rajbari in 2010 
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and claiming the lives of 14 of the 16 infected people. Whilst 
40 out of 44 registered cases died in Lalmohirhat, Dinajpur, 
Comilla, Nilphamari and Rangpur in early 2011. The final 
outbreak was in 2012 in Joypurhat, Rajshshi, Natore, and 
Rajbari with a fatality rate of 83% (n=12). In all instances, the 
identified risk factors were the consumption of raw date palm 
sap and direct contact with infected individuals. Infected fruit-
eating bats (Pteropus bats) were identified as a natural host for 
NiV [6]. 
In 2015, the Philippines National Epidemiology Centre 
received a report of 17 persons (11 with encephalitis, 5 with 
influenza like illness, and 1 with meningitis) and nonfatal 
infections with concurrent neurologic diseases and abrupt 
deaths in several horses. The mode of transmission was from 
direct exposure to infected horses, contact with contaminated 
body fluids during slaughtering of sick horses, and / or 
consumption of undercooked meat from infected horses [7].  
Recently, in the third NiV outbreak in India, in Kerala  17 
people from the districts of Malapuram and Kozhikode died in 
June 2018 and two recovered completely.  Again, it appeared 
that fruit eating bats were the primary source of infection and 
the public is warned not to eat fruits already partly eaten by 
bats. 
Since there is currently no effective specific treatment for 
Nipah virus infection, nor do we have any vaccines against it 
in humans or in animals, treatment is focused on dealing with 
the symptoms only.   
Recently Favipiravir, a purine analogue antiviral drug which 
was approved in Japan against influenza strains was found to 
be effective against the Nipah virus in inhibiting the 
replication and transcription at micromolar concentration in 
Syrian hamster model. But Favipiravir needs further 
evaluation before it can be used for the Nipah viruses [8].  
Antifusion lipopeptides has been found to be effective in for 
prophylaxis of lethal NiV in hamster and non-human primates. 
Antifusion lipopeptide inhibitors with a desired 
pharmacokinetic property could be targeted against NiV in 
future [9].  
For Public Health surveillance and multidisciplinary 
approaches on investigations and therapy and development of 
vaccines are vital.  As with all emerging viruses harmful to 
humans, an effective system for the detection of infectious 
diseases as well as for the identification for new causes, risk 
factors and characteristics in challenged settings is crucial to 
reduce the disease burden in the population. 
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